Regulatory readiness means knowing whether each tool is a regulated device, what its clearance and labeling permit, and being able to show an inspector how AI tools are controlled.
Regulatory readiness is the part of governance concerned with how external rules apply to each AI tool and how the organization would demonstrate control of those tools to an inspector or accreditor. It does not replace the internal program. It sets boundaries the internal program has to respect.
The FDA now reports more than 1,600 authorized AI-enabled medical devices, a milestone that shows market growth but not product quality or local clinical fit.
Aidoc has formed a 12-system Diagnostic AI Consortium as a Medicare add-on payment creates a new adoption opening for its Body CT Multi-Triage software.
Generative AI medical device risk assessment should connect clinical consequence, output variability, autonomy, human review, foundation model dependencies, and workflow controls.
Postmarket monitoring for generative AI medical devices should track output errors, corrections, clinical escalation, subgroup performance, dependencies, and model changes.
FDA's August 2026 discussion paper does not create new policy, but it shows how the agency is thinking about risk, competency assessment, monitoring, foundation models, and agentic AI in medical devices.
AI product release criteria help health systems and vendors decide whether a clinical AI tool is ready for pilot, go-live, expansion, or re-release after a model or workflow change.
FDA inspection readiness for AI-enabled clinical software is mainly quality-system readiness: intended use, design controls, software validation, risk management, change control, complaints, CAPA, labeling, and lifecycle records.
FDA clearance is an important signal for clinical AI, but it is not the whole evaluation. Research teams and hospital buyers need to read clearance, intended use, change control, local validation, and post-deployment monitoring together.
Software that is intended to diagnose, treat, or drive clinical management can meet the definition of a medical device, or software as a medical device. Whether a given tool does depends on its intended use and claims. Tools used for administrative support, or that only display information a clinician independently reviews, may fall outside device regulation. The classification drives how much external evidence and oversight applies.
A clearance defines the market pathway and oversight. It does not by itself prove clinical value in a given setting, which is why local validation still matters.
FDA's August 2026 discussion paper opened a new regulatory conversation around generative AI-enabled medical devices, including:
The paper is not guidance or policy.
It is still useful because it shows which questions manufacturers and health systems should be ready to answer.
AI models change. A predetermined change control plan describes, at the time of authorization, which modifications a manufacturer expects to make and how each will be validated. For a health system, a vendor with a clear plan makes change control far easier to manage.
The cleared intended use and labeling define the population, body part, modality, and clinical role the tool is authorized for. Governance should confirm that the deployed use matches the labeling and flag off-label use for extra review.
Being ready means being able to produce, on request, the model inventory, the risk tier and approval record for each tool, validation evidence, the monitoring plan and recent results, and the change-control history. See FDA AI Inspection Readiness for Clinical AI Software.